Frontline studies are ongoing to assess ALK inhibitor efficacy in ALK-positive PTCLs as compared to chemotherapy, similar to the approach used in NSCLC patients (clinicaltrial.gov ID NCT01979536). The gene discussed is ALK; the disease is non-small cell lung carcinoma.